CN106459201A - 结合人和食蟹猴CD3ε的抗体 - Google Patents

结合人和食蟹猴CD3ε的抗体 Download PDF

Info

Publication number
CN106459201A
CN106459201A CN201580026998.5A CN201580026998A CN106459201A CN 106459201 A CN106459201 A CN 106459201A CN 201580026998 A CN201580026998 A CN 201580026998A CN 106459201 A CN106459201 A CN 106459201A
Authority
CN
China
Prior art keywords
human
antibody
cells
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580026998.5A
Other languages
English (en)
Chinese (zh)
Inventor
G·蒂芬塔勒
E·默斯纳
V·利夫克
J·普拉策
S·奥夫纳
C·耶格
M·里特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN106459201A publication Critical patent/CN106459201A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580026998.5A 2014-05-28 2015-05-22 结合人和食蟹猴CD3ε的抗体 Pending CN106459201A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14170140.9 2014-05-28
EP14170140 2014-05-28
EP14180572.1 2014-08-11
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (1)

Publication Number Publication Date
CN106459201A true CN106459201A (zh) 2017-02-22

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580026998.5A Pending CN106459201A (zh) 2014-05-28 2015-05-22 结合人和食蟹猴CD3ε的抗体

Country Status (13)

Country Link
US (3) US20170233475A1 (enExample)
EP (2) EP3763739A1 (enExample)
JP (1) JP6738285B2 (enExample)
KR (1) KR20170003591A (enExample)
CN (1) CN106459201A (enExample)
AU (1) AU2015266077A1 (enExample)
BR (1) BR112016022819A2 (enExample)
CA (1) CA2942453A1 (enExample)
IL (1) IL247740A0 (enExample)
MX (1) MX2016015389A (enExample)
RU (1) RU2016151235A (enExample)
SG (1) SG11201609950YA (enExample)
WO (1) WO2015181098A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111417719A (zh) * 2017-11-30 2020-07-14 豪夫迈·罗氏有限公司 B细胞培养方法
WO2023273762A1 (zh) * 2021-06-30 2023-01-05 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2901794T3 (es) 2015-12-09 2022-03-23 Hoffmann La Roche Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
CA3059010A1 (en) 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
FI3561057T3 (fi) * 2016-12-22 2025-10-07 Daiichi Sankyo Co Ltd Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3634998B8 (en) * 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
TWI820041B (zh) * 2017-09-21 2023-11-01 中國大陸商上海藥明生物技術有限公司 新型抗CD3ε抗體
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
CA3093330A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
MX420253B (es) * 2018-05-24 2025-02-10 Janssen Biotech Inc Anticuerpos anti-cd3 y usos de estos.
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
IL298444A (en) * 2020-05-27 2023-01-01 Janssen Biotech Inc Proteins containing cd3 antigen binding sites and uses thereof
JP2023542209A (ja) * 2020-09-24 2023-10-05 モルフォシス・アーゲー ヒトｃｄ３イプシロンに結合する新規なヒト抗体
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
EP4314075A4 (en) * 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4329800A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
US20230295310A1 (en) * 2022-03-20 2023-09-21 Abcellera Biologics Inc. CD3 T-Cell Engagers and Methods of Use
KR20240158351A (ko) * 2022-03-22 2024-11-04 모르포시스 아게 Cd3에 특이적인 탈면역화 항체
MX2024011468A (es) 2022-03-23 2024-09-25 Hoffmann La Roche Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
AU2023251832A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
DK2155788T3 (da) * 2007-04-03 2012-10-08 Amgen Res Munich Gmbh Krydsartsspecifikke bispecifikke bindemidler
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111417719A (zh) * 2017-11-30 2020-07-14 豪夫迈·罗氏有限公司 B细胞培养方法
CN111417719B (zh) * 2017-11-30 2023-08-29 豪夫迈·罗氏有限公司 B细胞培养方法
WO2023273762A1 (zh) * 2021-06-30 2023-01-05 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用

Also Published As

Publication number Publication date
RU2016151235A3 (enExample) 2019-01-18
RU2016151235A (ru) 2018-06-28
US20200299385A1 (en) 2020-09-24
US20200325224A1 (en) 2020-10-15
KR20170003591A (ko) 2017-01-09
CA2942453A1 (en) 2015-12-03
JP6738285B2 (ja) 2020-08-12
MX2016015389A (es) 2017-04-13
AU2015266077A1 (en) 2016-09-29
SG11201609950YA (en) 2016-12-29
IL247740A0 (en) 2016-11-30
BR112016022819A2 (pt) 2018-01-16
EP3763739A1 (en) 2021-01-13
JP2017516786A (ja) 2017-06-22
US20170233475A1 (en) 2017-08-17
EP3149041A1 (en) 2017-04-05
WO2015181098A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
US20230279109A1 (en) Anti-tim3 antibodies and methods of use
US20200299385A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
JP7592050B2 (ja) 抗ｈｌａ－ｇ抗体とその使用
US20250051456A1 (en) Anti-hla-g antibodies and methods of use thereof
CN108368173B (zh) 抗pd1抗体及使用方法
JP2019500853A (ja) 抗ｔｐｂｇ抗体と使用方法
HK1231092A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
HK40011622B (en) Anti-hla-g antibodies and use thereof
HK1259019B (zh) 抗pd1抗体及使用方法
HK1241906B (zh) 抗tim3抗体及使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231092

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20210730

AD01 Patent right deemed abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1231092

Country of ref document: HK